Johnson & Johnson stock (US4781601046): Oncology data and device recall shape investor focus

Johnson & Johnson stock on the New York Stock Exchange traded around recent levels in late May as the United States-based healthcare group combined fresh oncology study data with a new medical device recall at its Abiomed business, drawing investor attention to both its pharmaceuticals growth engine and execution risks in medical technology, according to company statements and industry reports as of 05/29/2026.

In a press release from Chicago dated 05/29/2026, Johnson & Johnson reported that the Phase 3 MajesTEC-9 study showed clinically meaningful and statistically significant improvements in progression-free survival and overall survival for TECVAYLI (teclistamab-cqyv) versus standard of care regimens in adults with relapsed or refractory multiple myeloma who were treated as early as second line, reinforcing the company’s positioning as a key United States innovator in multiple myeloma therapies, according to Johnson & Johnson as of 05/29/2026.

The group highlighted that the MajesTEC-9 results build on the U.S. Food and Drug Administration’s March 2026 approval of TECVAYLI in combination with DARZALEX FASPRO for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, further underpinning U.S. revenue prospects in oncology as detailed in the same company communication dated 05/29/2026.

Also on 05/29/2026 in Chicago, Johnson & Johnson presented updated Phase 1/1b CHRYSALIS-2 data for RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) in advanced non-small cell lung cancer with atypical EGFR mutations, reporting a median overall survival of nearly 3.5 years and consistent responses across atypical mutation subgroups, with a safety profile broadly aligned with earlier reports and no new safety signals, according to Johnson & Johnson as of 05/29/2026.

These oncology updates come as Abiomed, a Johnson & Johnson medical technology business, initiated a recall of certain Impella heart pumps after a patient death, with the unit asking customers to quarantine and return affected products in a notice reported on 05/29/2026, underscoring that part of the U.S. group’s device portfolio is under regulatory and operational scrutiny, according to MedTech Dive as of 05/29/2026.

The stock traded in the United States under the ticker JNJ on the NYSE, with investors weighing these latest trial readouts and the Abiomed recall against the company’s broader financial profile, while trading in euros on platforms such as Tradegate in Germany offers an additional access route for European retail investors as of late May 2026 based on exchange data.

The company continues to emphasize its U.S. investor relations infrastructure with dedicated contacts for oncology media and shareholder inquiries, reflecting the importance of New York and broader United States capital markets for its funding and valuation, as noted in the same 05/29/2026 press materials.

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

Johnson & Johnson: core business model

Johnson & Johnson operates as a diversified healthcare group that generates revenue primarily from patented prescription medicines, including oncology therapies, alongside medical technology products such as cardiovascular devices and surgical solutions.

Recent corporate actions

Within the past 90 days, Johnson & Johnson’s Abiomed unit has stood out for its recall of Impella heart pumps after one reported patient death, as detailed in a 05/29/2026 article stating that customers were instructed to quarantine and return affected devices, a step that highlights the ongoing regulatory oversight and potential remediation costs in the company’s United States-centered medtech operations, according to MedTech Dive as of 05/29/2026.

Insider activity and ownership structure

Recent filings and public disclosures indicate that Johnson & Johnson remains widely held by institutional investors such as mutual funds, pension funds and index products that track major United States benchmarks including the S&P 500, with no transformative insider ownership changes disclosed in the latest available regulatory documents as of late May 2026.

While specific Form 4 insider transactions have not featured prominently in the past few weeks, the company continues to report director and executive dealings through U.S. Securities and Exchange Commission channels in line with standard practice for NYSE-listed blue chips, and its broad free float supports liquidity for retail and professional investors alike in the United States and abroad as of 05/30/2026.

Conclusion

The latest ASCO 2026 updates on TECVAYLI and RYBREVANT underline Johnson & Johnson’s strategy of building its United States-led pharmaceuticals pipeline around oncology assets with differentiated survival data, while regulatory-approved combinations such as TECVAYLI plus DARZALEX FASPRO may support medium-term revenue growth in multiple myeloma.

At the same time, the Impella heart pump recall at Abiomed serves as a reminder that the group’s medtech portfolio must continually meet stringent safety expectations, and investors will monitor how quality initiatives and any associated costs interact with the company’s broader capital allocation, dividend policy and research investment plans going forward.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.